NGM Stock Overview
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
NGM Biopharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.09 |
| 52 Week High | US$18.25 |
| 52 Week Low | US$2.92 |
| Beta | 1.22 |
| 1 Month Change | 1.39% |
| 3 Month Change | -4.14% |
| 1 Year Change | -67.81% |
| 3 Year Change | -70.04% |
| 5 Year Change | n/a |
| Change since IPO | -65.37% |
Recent News & Updates
Recent updates
We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully
Dec 20
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Jun 15Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week
May 09Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Feb 21We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely
Nov 08Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Jul 09NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Mar 06We're Not Very Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate
Mar 02Update: NGM Biopharmaceuticals (NASDAQ:NGM) Stock Gained 56% In The Last Year
Jan 26
Here's What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Shareholder Ownership Structure Looks Like
Dec 22Have Insiders Been Selling NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Shares?
Nov 26Shareholder Returns
| NGM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.4% | -1.4% | 2.8% |
| 1Y | -67.8% | 4.5% | -9.2% |
Return vs Industry: NGM underperformed the US Pharmaceuticals industry which returned 4.5% over the past year.
Return vs Market: NGM underperformed the US Market which returned -9.2% over the past year.
Price Volatility
| NGM volatility | |
|---|---|
| NGM Average Weekly Movement | 8.6% |
| Pharmaceuticals Industry Average Movement | 11.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: NGM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: NGM's weekly volatility has decreased from 14% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 225 | David Woodhouse | https://www.ngmbio.com |
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company’s product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors.
NGM Biopharmaceuticals, Inc. Fundamentals Summary
| NGM fundamental statistics | |
|---|---|
| Market Cap | US$415.99m |
| Earnings (TTM) | -US$153.46m |
| Revenue (TTM) | US$58.11m |
7.2x
P/S Ratio-2.7x
P/E RatioIs NGM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NGM income statement (TTM) | |
|---|---|
| Revenue | US$58.11m |
| Cost of Revenue | US$173.07m |
| Gross Profit | -US$114.96m |
| Other Expenses | US$38.50m |
| Earnings | -US$153.46m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.88 |
| Gross Margin | -197.83% |
| Net Profit Margin | -264.09% |
| Debt/Equity Ratio | 0% |
How did NGM perform over the long term?
See historical performance and comparison